LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stock Market LLC (Nasdaq), it has submitted its plan to Nasdaq to regain compliance with the minimum bid price requirement and the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. On May 29, 2025, the Company requested a hearing before The Nasdaq ...

TaoAvatar 是由阿里巴巴淘宝 Meta 技术团队研发的 3D 真人数字人技术，这一技术能在手机或 XR 设备上实现 3D 数字人的实时渲染以及 AI 对话的强大 功能，为用户带来逼真的虚拟交互体验。 它是如何实现的呢？本文将为您揭秘 TaoAvatar 背后的黑科技！同时在今天，我们正式宣布开源了 3D 真人数字人应用：MNN-TaoAvatar！目前应用源 码已同步发布在 MNN 的 GitHub 仓库，开发者可自行下载安装和体验，欢迎大家和我们一起交流讨论，共同探索 AI 数字人技术的无限可能。 什么是 TaoAvatar？ TaoAvatar 是淘宝在数字人技术领域取得的最新突破，更多详细的研究成果已经发表在相关论文。 论文标题：TaoAvatar: Real-Time Lifelike Full-Body Talking Avatars for Augmented Reality via 3D Gaussian Splatting 论文地址：https://arxiv.org/abs/2503.17032v1 开源地址: https://github.com/alibaba/MNN/blob/ ...

证券研究报告 | 2025年06月19日 人工智能周报（25 年第 24 周） 优于大市 OpenAI 上线 o3-pro 模型，字节跳动发布豆包大模型 1.6 人工智能动态：1）产品应用：OpenAI 上线 o3-pro AI 模型，兼具高效 性能与精准输出能力；Meta 推出世界模型 V-JEPA 2，具备卓越环境理 解与预测能力；苹果发布 Xcode26 开发者工具，内置 ChatGPT 赋能开发； 字节跳动发布豆包大模型 1.6，采用统一定价模式；阿里开源 3D 数字人 应用，革新直播与虚拟互动体验；腾讯混元 3D 2.1 全链路开源，几何 生成与材质表现显著提升。2）底层技术：阿里通义实验室开源 Mask Search 预训练框架，提升 AI 复杂问题解决表现；DeepMind 与布朗大学 合作开发"力提示"技术，实现无 3D 模型逼真运动效果 3）行业政策： 工业和信息化部会议审议《2025 年两化融合工作要点》，部署推进策略。 投资建议：互联网一季报披露完毕，业绩整体稳健。电商行业竞争依旧 激烈，各平台选择继续向商家让利、或在外卖即时零售领域加大投入寻 找新增量。AI 方面，巨头的业务场景，如云 ...

证券研究报告 | 2025年06月19日 人工智能周报（25 年第 24 周） 优于大市 OpenAI 上线 o3-pro 模型，字节跳动发布豆包大模型 1.6 人工智能动态：1）产品应用：OpenAI 上线 o3-pro AI 模型，兼具高效 性能与精准输出能力；Meta 推出世界模型 V-JEPA 2，具备卓越环境理 解与预测能力；苹果发布 Xcode26 开发者工具，内置 ChatGPT 赋能开发； 字节跳动发布豆包大模型 1.6，采用统一定价模式；阿里开源 3D 数字人 应用，革新直播与虚拟互动体验；腾讯混元 3D 2.1 全链路开源，几何 生成与材质表现显著提升。2）底层技术：阿里通义实验室开源 Mask Search 预训练框架，提升 AI 复杂问题解决表现；DeepMind 与布朗大学 合作开发"力提示"技术，实现无 3D 模型逼真运动效果 3）行业政策： 工业和信息化部会议审议《2025 年两化融合工作要点》，部署推进策略。 投资建议：互联网一季报披露完毕，业绩整体稳健。电商行业竞争依旧 激烈，各平台选择继续向商家让利、或在外卖即时零售领域加大投入寻 找新增量。AI 方面，巨头的业务场景，如云 ...

Core Insights - IMUNON, Inc. announced positive results from a Phase 1 clinical trial of its investigational DNA plasmid vaccine, IMNN-101, which demonstrated better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 variant [3][4] - The company is seeking strategic partnerships to advance its PlaCCine technology platform and fund its core pipeline with non-dilutive capital [1][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing non-viral DNA-mediated immunotherapies and next-generation vaccines [1][8] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, which has completed multiple clinical trials [9] Clinical Trial Details - The Phase 1 trial enrolled 24 participants and evaluated three escalating doses of IMNN-101, with a focus on safety, tolerability, and immunogenicity [6] - Results indicated a median increase of up to 3-fold in serum neutralizing antibody titers at six months, with no serious adverse effects reported [3][6] Technology Advantages - The PlaCCine technology platform offers several competitive advantages, including better durability of protection, temperature stability, and ease of manufacturing compared to current mRNA vaccines [4][5] - IMNN-101 utilizes a proprietary DNA plasmid that regulates the expression of key pathogen antigens, providing flexibility in manufacturing and delivery [5]

Core Points - IMUNON, Inc. is a clinical-stage biotechnology company focused on DNA-mediated immunotherapy, currently in Phase 3 development [1][4] - The company will present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12, 2025, at 11:30 a.m. ET [1] - IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, having completed multiple clinical trials including a Phase 2 trial [5] Company Overview - IMUNON is developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases, differentiating from conventional therapies [4] - The company is advancing its non-viral DNA technology through two main modalities: TheraPlas for gene-based delivery of cytokines and PlaCCine for gene delivery of viral antigens [4] Clinical Programs - IMNN-001 instructs the body to produce cancer-fighting molecules at the tumor site, specifically interleukin-12 and interferon gamma [5] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101 [5] - IMUNON aims to leverage its technologies to address difficult-to-treat conditions, either directly or through partnerships [5]

Core Insights - IMUNON, Inc. announced positive results from its Phase 2 OVATION 2 Study, demonstrating the efficacy of IMNN-001 in improving overall survival and progression-free survival in women with newly diagnosed advanced ovarian cancer [1][4][9] Group 1: Study Results - The Phase 2 OVATION 2 Study involved 112 participants randomized to receive IMNN-001 plus neoadjuvant and adjuvant chemotherapy versus standard of care, with a median follow-up of 31 months [2][5] - IMNN-001 treatment resulted in a median overall survival increase of 13 months (46 months vs. 33 months) and a median progression-free survival increase of 3 months (14.9 months vs. 11.9 months) compared to standard care [4][5] - The chemotherapy response score indicated a response rate of 26.1% in the IMNN-001 group versus 13.0% in the control group, highlighting a significant therapeutic effect [4] Group 2: Safety Profile - IMNN-001 exhibited a favorable safety profile with no serious immune-related adverse events reported, and the most common adverse events included abdominal pain, nausea, and vomiting [4][6] - The study showed a surgical response rate of 64.6% for the IMNN-001 treatment arm compared to 52.1% for the control arm, indicating better surgical outcomes [4] Group 3: Mechanism and Technology - IMNN-001 is based on IMUNON's proprietary TheraPlas technology, designed to induce a potent anti-cancer immune response through the local secretion of IL-12 [6][9] - The treatment is particularly effective in patients with homologous recombination deficiency (HRD+), including those with BRCA1 and BRCA2 mutations, as indicated by a hazard ratio of 0.42 [4][6] Group 4: Future Directions - The company plans to advance its pivotal Phase 3 OVATION 3 trial of IMNN-001, with initial trial sites recently initiated [3][9] - IMUNON aims to leverage its non-viral DNA technology to develop innovative treatments for various diseases, focusing on solid tumors [8][9]

Core Insights - IMUNON, Inc. has made significant progress in advancing cancer treatment, particularly with its lead candidate IMNN-001 for ovarian cancer, which is currently in the pivotal Phase 3 OVATION 3 Study [1][2][7] Group 1: Clinical Developments - IMNN-001 has shown promising results in the Phase 2 OVATION 2 Study, demonstrating a median overall survival (OS) extension of 13 months compared to standard-of-care treatments [4] - The drug has a favorable safety profile, with manageable adverse events and no reports of severe immune-related issues, positioning it as a first-in-class immunotherapy [4][5] - Enhanced efficacy has been observed in patients receiving PARP inhibitors, with median OS not yet reached in the IMNN-001 arm after over five years [4] Group 2: Financial and Strategic Positioning - The company has attracted interest from institutional investors, reflecting confidence in its scientific advancements and strategic direction [6] - IMUNON is strategically managing its resources to fund the Phase 3 trial while aligning its critical needs with available capital [6] - The recent increase in share price positions the company favorably to meet NASDAQ listing requirements [6] Group 3: Future Outlook - IMUNON is poised for transformative growth with a clear financial strategy and compelling clinical data supporting its TheraPlas platform [7] - The company aims to deliver innovative treatment options for patients with ovarian cancer while creating sustainable value for shareholders [7][8]

Core Viewpoint - IMUNON, Inc. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from short-term warrants [1][3]. Group 1: Financial Details - The company sold 7,222,223 shares of common stock at a price of $0.45 per share, along with short-term warrants to purchase up to 14,444,446 additional shares [1]. - The total gross proceeds from the private placement are approximately $3.25 million before deducting fees and expenses [3]. - If fully exercised, the short-term warrants could provide an additional $6.5 million in gross proceeds [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory and Offering Details - The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act [4]. - The offering was made only to accredited investors, and the company has agreed to file registration statements with the SEC for resale of the shares [4]. Group 4: Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments using non-viral DNA technology [6]. - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, which has completed multiple clinical trials [7]. - IMUNON is also advancing a COVID-19 booster vaccine (IMNN-101) and aims to leverage its technologies to address difficult-to-treat conditions [7].

Core Insights - IMUNON, Inc. is advancing its DNA-mediated immunotherapy, IMNN-001, which shows promising survival data for women with advanced ovarian cancer, with presentations scheduled at major oncology conferences [1][2][4] - The OVATION 2 Study demonstrated significant improvements in overall survival and progression-free survival for patients treated with IMNN-001 in combination with standard chemotherapy [2][5] - IMNN-001 utilizes a proprietary TheraPlas technology platform, delivering interleukin-12 (IL-12) to enhance anti-cancer immunity, marking it as the first IL-12 immunotherapy to show clinical efficacy in advanced ovarian cancer [3][7] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that leverage the body's immune response, with a particular emphasis on non-viral DNA technology [9][10] - The company is developing multiple modalities, including TheraPlas for gene-based delivery of cytokines and PlaCCine for viral antigens, aiming to address solid tumors and other challenging conditions [9][10] Study Details - The Phase 2 OVATION 2 Study involved 112 patients with newly diagnosed advanced epithelial ovarian cancer, evaluating the safety and efficacy of IMNN-001 combined with neoadjuvant and adjuvant chemotherapy [5][6] - The study's design included a randomized approach comparing IMNN-001 plus standard chemotherapy against standard chemotherapy alone, focusing on overall survival as the primary endpoint [4][6] Future Directions - IMUNON is preparing for the pivotal Phase 3 OVATION 3 Study, which will further assess IMNN-001 in a larger cohort of women with advanced ovarian cancer, including those with specific genetic mutations [4][10] - The company anticipates regulatory review for IMNN-001 in the European Union and other global markets, aiming to improve treatment standards for advanced ovarian cancer [4][10]